WhitTier Trust Company’s Catalyst Pharmaceutical CPRX Stock Holding History

WhitTier Trust Company’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-970	Closed	-$24.2K	–	1438
2026 Q1	$24.2K	Hold	970	–	–	﹤0.01%	859
2025 Q4	$21.9K	Sell	970 -14	-1%	-$312	﹤0.01%	890
2025 Q3	$20.5K	Sell	984 -16	-2%	-$329	﹤0.01%	891
2025 Q2	$21.7K	Hold	1,000	–	–	﹤0.01%	970
2025 Q1	$24.3K	Buy	1,000 +8	+0.8%	+$180	﹤0.01%	926
2024 Q4	$20.7K	Buy	+992	New	+$21.3K	﹤0.01%	940

Other funds holding CPRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

WhitTier Trust Company's CPRX Position: Q2 2026 in Review

WhitTier Trust Company sold out of Catalyst Pharmaceutical (CPRX) in Q2 2026, closing a stake of 970 shares — an estimated $24.2K sold.

WhitTier Trust Company first reported a position in CPRX in Q4 2024 and held it in 6 quarters. The position peaked at $24.3K in Q1 2025. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

WhitTier Trust Company reported no remaining Catalyst Pharmaceutical position as of Q2 2026 after selling out during the quarter.
WhitTier Trust Company sold 970 Catalyst Pharmaceutical shares in Q2 2026, an estimated $24.2K.
WhitTier Trust Company first reported a position in Catalyst Pharmaceutical in Q4 2024 and held it in 6 quarters.
WhitTier Trust Company's Catalyst Pharmaceutical position peaked at $24.3K in Q1 2025.
396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on WhitTier Trust Company's 13F filing for Q2 2026, filed 28 Jul 2026.